Skip Navigation
Skip to contents




15 results

Response: Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation (Endocrinol Metab 2014;29:33-9, Eon Ju Jeon et al.)

Jeon EJ, Jung ED

  • Endocrinol Metab.
  • 2014 Jun;29(2):208-209.
  • doi: 10.3803/EnM.2014.29.2.208
No abstract available.
Letter: Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation (Endocrinol Metab 2014;29:33-9, Eon Ju Jeon et al.)

Jung CH

  • Endocrinol Metab.
  • 2014 Jun;29(2):206-207.
  • doi: 10.3803/EnM.2014.29.2.206
No abstract available.
Recurrent Hypoglycemia Triggered by Sorafenib Therapy in a Patient with Hemangiopericytoma

Lee SW, Lee EK, Yun T, Won YW, Ko EJ, Choi M, Choi SI, Park SS, Hong EK

  • Endocrinol Metab.
  • 2014 Jun;29(2):202-205.
  • doi: 10.3803/EnM.2014.29.2.202
Targeted therapy has been proven to be one of the most effective cancer treatments. However, some endocrine disorders can occur during treatment with targeted agents. We report the case of...
A Novel PHEX Gene Mutation in a Patient with Sporadic Hypophosphatemic Rickets

Kang YE, Hong JH, Kim J, Joung KH, Kim HJ, Ku BJ, Kim KS

  • Endocrinol Metab.
  • 2014 Jun;29(2):195-201.
  • doi: 10.3803/EnM.2014.29.2.195
Phosphate regulating gene with homologies to endopeptidases on the X-chromosome (PHEX) is a common cause of X-linked hypophosphatemic (XLH) rickets. Diverse PHEX gene mutations have been reported; however, gene mutations...
A Novel Cytosolic Isoform of Mitochondrial Trans-2-Enoyl-CoA Reductase Enhances Peroxisome Proliferator-Activated Receptor alpha Activity

Kim DG, Yoo JC, Kim E, Lee YS, Yarishkin , Lee DY, Lee KH, Hong SG, Hwang EM, Park JY

  • Endocrinol Metab.
  • 2014 Jun;29(2):185-194.
  • doi: 10.3803/EnM.2014.29.2.185
BACKGROUND: Mitochondrial trans-2-enoyl-CoA reductase (MECR) is involved in mitochondrial synthesis of fatty acids and is highly expressed in mitochondria. MECR is also known as nuclear receptor binding factor-1, which was...
Gene Expression Regulation by Agonist-Independent Constitutive Signaling of Melanocortin-1 Receptor

Seong I, Kim J

  • Endocrinol Metab.
  • 2014 Jun;29(2):179-184.
  • doi: 10.3803/EnM.2014.29.2.179
BACKGROUND: Melanocortin-1 receptor (Mc1r), a key signaling receptor for melanogenesis, has been reported to mediate migration of B16F10 melanoma cells. Interestingly, this activity appears to be a part of the...
Highly Palatable Food during Adolescence Improves Anxiety-Like Behaviors and Hypothalamic-Pituitary-Adrenal Axis Dysfunction in Rats that Experienced Neonatal Maternal Separation

Lee JH, Kim JY, Jahng JW

  • Endocrinol Metab.
  • 2014 Jun;29(2):169-178.
  • doi: 10.3803/EnM.2014.29.2.169
BACKGROUND: This study was conducted to examine the effects of ad libitum consumption of highly palatable food (HPF) during adolescence on the adverse behavioral outcome of neonatal maternal separation. METHODS: Male...
Insulin Phosphorylates Tyrosine Residue 464 of Tub and Translocates Tubby into the Nucleus in HIRcB Cells

Kim JW, Kim HS, Kim SD, Park JY

  • Endocrinol Metab.
  • 2014 Jun;29(2):163-168.
  • doi: 10.3803/EnM.2014.29.2.163
BACKGROUND: The tubby protein has a motif that might be relevant for its action in the insulin signaling pathway. Previous studies have indicated that tubby undergoes phosphorylation on tyrosine residues...
The Biochemical Prognostic Factors of Subclinical Hypothyroidism

Lee MW, Shin DY, Kim KJ, Hwang S, Lee EJ

  • Endocrinol Metab.
  • 2014 Jun;29(2):154-162.
  • doi: 10.3803/EnM.2014.29.2.154
BACKGROUND: Patients with subclinical hypothyroidism (SHT) are common in clinical practice. However, the clinical significance of SHT, including prognosis, has not been established. Further clarifying SHT will be critical in...
Genetic Analysis of Multiple Endocrine Neoplasia Type 1 (MEN1) Leads to Misdiagnosis of an Extremely Rare Presentation of Intrasellar Cavernous Hemangioma as MEN1

Lee DM, Yu SH, Yoon HH, Lee KL, Eom YS, Lee K, Kim BJ, Kim YS, Park IB, Kim KW, Lee S

  • Endocrinol Metab.
  • 2014 Jun;29(2):146-153.
  • doi: 10.3803/EnM.2014.29.2.146
BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited disorder characterized by the simultaneous occurrence of endocrine tumors in target tissues (mainly the pituitary, endocrine pancreas, and parathyroid...
The Biochemical Prognostic Factors of Subclinical Hypothyroidism

Lee YJ

  • Endocrinol Metab.
  • 2014 Jun;29(2):144-145.
  • doi: 10.3803/EnM.2014.29.2.144
No abstract available.
Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia

Fukumoto S

  • Endocrinol Metab.
  • 2014 Jun;29(2):136-143.
  • doi: 10.3803/EnM.2014.29.2.136
Fibroblast growth factor 23 (FGF23) is a hormone that is produced by osteocytes and regulates phosphate and vitamin D metabolism through binding to the Klotho-FGF receptor complex. Excessive actions of...
Regulation of Adipocyte Differentiation via MicroRNAs

Son YH, Ka S, Kim AY, Kim JB

  • Endocrinol Metab.
  • 2014 Jun;29(2):122-135.
  • doi: 10.3803/EnM.2014.29.2.122
Adipocyte differentiation, termed adipogenesis, is a complicated process in which pluripotent mesenchymal stem cells differentiate into mature adipocytes. The process of adipocyte differentiation is tightly regulated by a number of...
Neurocognitive Changes and Their Neural Correlates in Patients with Type 2 Diabetes Mellitus

Lee JH, Choi Y, Jun C, Hong YS, Cho HB, Kim JE, Lyoo IK

  • Endocrinol Metab.
  • 2014 Jun;29(2):112-121.
  • doi: 10.3803/EnM.2014.29.2.112
As the prevalence and life expectancy of type 2 diabetes mellitus (T2DM) continue to increase, the importance of effective detection and intervention for the complications of T2DM, especially neurocognitive complications...
Transcriptional Regulation of Fibroblast Growth Factor 21 Expression

Bae KH, Kim JG, Park KG

  • Endocrinol Metab.
  • 2014 Jun;29(2):105-111.
  • doi: 10.3803/EnM.2014.29.2.105
Fibroblast growth factor 21 (FGF21) is an attractive target for treating metabolic disease due to its wide-ranging beneficial effects on glucose and lipid metabolism. Circulating FGF21 levels are increased in...

Go to Top

Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: